neuroClues develops an eye-tracking platform that quantifies eye movement biomarkers to enhance the diagnosis and monitoring of neurological diseases. This technology enables healthcare practitioners to obtain objective measurements of disease progression and treatment efficacy, potentially years before traditional symptoms appear.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAWFFounders
Product
Problem
Diagnosing and monitoring neurological diseases often relies on subjective assessments and may not detect subtle changes in disease progression until symptoms are overtly apparent. Traditional neurological exams may lack the sensitivity to differentiate between similar conditions or to accurately track treatment efficacy.
Solution
neuroClues offers an eye-tracking platform that provides objective, quantifiable biomarkers to aid in the diagnosis and monitoring of neurological diseases. The platform analyzes eye movements to identify patterns associated with various neurological conditions, potentially enabling earlier detection and more accurate differentiation between diseases like Parkinson's, atypical parkinsonian syndromes, Alzheimer's, and multiple sclerosis. By tracking changes in oculomotor function, neuroClues supports the monitoring of disease progression and the evaluation of treatment effectiveness, offering a more sensitive and reliable method compared to traditional clinical scales. The technology aims to translate decades of neuroscientific research on eye movements into a practical clinical tool, providing practitioners with an easy-to-use system for quantifying neurological examinations.
Target Audience
The primary target audience includes neurologists, ophthalmologists, clinical researchers, and pharmaceutical companies involved in developing and testing treatments for neurological diseases.
Features
- Non-invasive eye-tracking technology for rapid assessment of oculomotor function
- Quantification of eye movement biomarkers linked to various neurological disorders
- Detection of subtle changes in eye movement patterns indicative of disease progression
- Support for differential diagnosis between conditions with similar clinical presentations
- Objective measurements for evaluating the efficacy of neurological treatments
- Integration of research-backed scientific knowledge into a user-friendly clinical tool
- CE-marked as a Class IIa medical device in the European Union
- Pupillometry analysis with a new method to improve accuracy by comparing pupil size to the size of the limbus